Vancouver, British Columbia — A highly controlled retrospective analysis suggests that denosumab (Prolia) leads to greater reduction in fracture risk than does zoledronic acid (Reclast ...

Osteoporosis is a bone disease that develops when bone mineral density and bone mass decrease or when bone strength and structure change. People living with osteoporosis typically do not have ...

Denosumab (Prolia®, Xgeva®) reversed cortical bone ... and from a change in bone structure. Osteoporosis can increase fracture risk. Risk factors for developing osteoporosis include a sedentary ...